BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

Neuropathic pain syndrome is a challenge to treat and, even with appropriate evidence-based treatment, only a 40% reduction of symptoms can be achieved in approximately half of patients.

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for ...

Lidocaine, along with other topical creams, can help treat nerve pain near the skin’s surface, a condition called peripheral neuropathy. Lidocaine provides temporary relief by blocking the ...

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

“With the rising incidence of diabetes globally, the burden of neuropathic pain is becoming increasingly prominent,” said a FMI. “Our report indicates that the nerve entrapment syndrome therapeutics ...

Professor Kim Jung-soo of the Department of Anesthesiology Pain Medicine at Seoul National University Hospital won the '2024 ...